Nuzenio

Azacitidine

Azacitidine news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 4 publisher sources 100/100 entity strength

Latest news

New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 15:20:44 GMT Shorter Venetoclax Plus Azacitidine Schedule Falls Short in AML - OncLiveOncLive · Fri, 31 Jul 2026 20:53:14 GMT Implications of the Negative VERONA Trial of Venetoclax/Azacitidine in Higher-Risk MDS - OncLiveOncLive · Fri, 31 Jul 2026 14:03:07 GMT Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML - PR NewswirePR Newswire · Thu, 30 Jul 2026 18:30:00 GMT Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine - NatureNature · Thu, 30 Jul 2026 16:47:03 GMT Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS - The ASCO PostThe ASCO Post · Tue, 28 Jul 2026 14:04:33 GMT

Timeline

Thu, 06 Aug 2026 15:20:44 GMTNew Data on 14- vs 28-Day Venetoclax/Azacitidine in AML - The ASCO Post

Fri, 31 Jul 2026 20:53:14 GMTShorter Venetoclax Plus Azacitidine Schedule Falls Short in AML - OncLive

Fri, 31 Jul 2026 14:03:07 GMTImplications of the Negative VERONA Trial of Venetoclax/Azacitidine in Higher-Risk MDS - OncLive

Thu, 30 Jul 2026 18:30:00 GMTBeat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML - PR Newswire

Thu, 30 Jul 2026 16:47:03 GMTVenetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine - Nature

Tue, 28 Jul 2026 14:04:33 GMTPhase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS - The ASCO Post

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

AML6 live mentions Day Venetoclax4 live mentions Higher4 live mentions Venetoclax3 live mentions New Data2 live mentions The ASCO Post2 live mentions Negative VERONA Trial2 live mentions Risk MDS2 live mentions Study Provides New2 live mentions Data2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Azacitidine.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.